anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vicarious trauma (VT) is an occupational challenge incurred through hearing about traumatic experiences of others such as child maltreatment, mass casualties, and others while serving in helping professions. Without sufficient resources and support, long-term exposure can lead to symptoms such as intrusion, avoidance, arousal, emotional numbing, anxiety, and decline in one's ability to work. Organisations can mitigate VT's impact by addressing the needs of staff through 5 evidence-informed areas of occupational health. This project explored the impact of VT-informed practices on organisational responses to the COVID-19 pandemic. We compared responses from 50 organisations on strengths and weaknesses in core areas of being VT-informed to how those organisations responded to the COVID-19 pandemic. Subscales of the VT Organizational Readiness Guide (VT-ORG) were utilized as the exposure variables and 4 new COVID-19 questions served as the outcome. We ran a series of multilevel linear regression models with clustering controlled for at the organisational level. Staff ratings on 4 of the 5 pillars of the VT-ORG were positively associated with the organisation's responsiveness to the pandemic. Various demographic factors of the employees were negatively associated with organisations' responsiveness to the pandemic. While this study contributes to the growing research on VT, it also provides justification for helping organisations to become VT-informed; it provides evidence that being prepared for VT can also be useful to support workers and their communities during emergencies such as the COVID-19 pandemic.
<P>PROBLEM TO BE SOLVED: To provide a water-dispersible fiber and fibrous articles prepared therefrom that exhibit adequate tensile strength, absorptivity, flexibility, and fabric integrity in the presence of moisture, especially upon exposure to human bodily fluids (a fibrous article is needed that does not require a binder and completely disperses or dissolves in residential or municipal sewerage systems).  <P>SOLUTION: There are disclosed water-dispersible fibers derived from sulfopolyesters having a Tg of at least 25°C, or a blend of a sulfopolyester with a water-dispersible or water-nondispersible polymer. Also, there are disclosed multicomponent fibers comprising a water dispersible sulfopolyester having a Tg of at least 57°C and a water non-dispersible polymer. The multicomponent fibers may be used to produce microdenier fibers. Fibrous articles may be produced from the water-dispersible fibers, multicomponent fibers, and microdenier fibers.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Multicomponent nanoparticles and their use. The invention relates to multicomponent nanoparticles for transfection and cell selection. The nanoparticles comprise (a) superparamagnetic iron oxide (SPION) nanoparticles, (b) a polymer that is a poly (beta-amino ester) (pBAE) modified at the ends with at least one oligopeptide and having a molecular mass of between 1,000 and 10,000 Da and (c) a polynucleotide. These multicomponent particles enhance the transfection efficiency of non-viral chemical administration in different cell types. In addition, the magnetic characteristic of these innovative nanoparticles allows the rapid and massive separation of cells that contain particles by applying a strong magnetic field. (Machine-translation by Google Translate, not legally binding)
Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
1. To explore and illuminate the cultural, social, and psychological factors that either facilitate or serve as barriers to behavioral change in angioplasty patients. Through a series of open-ended questions we will explore and build a better understanding of how culturally different patient groups perceive heart disease and the difficulties in changing health behavior. In addition, we hope to better understand and anticipate barriers and issues that participants face in successfully changing their behaviors.
2. To use the responses obtained in the qualitative interviews to inform how we should operationalize and tailor the positive affect induction and self-affirmation intervention methods in each of the populations under study. Specifically, this involves assessing what small gifts participants prefer to receive and what would be most effective in inducing positive affect.
BACKGROUND: Despite the high recurrence rate of non-muscle-invasive bladder cancer (NMIBC), there are limitations in accurately predicting recurrence after transurethral resection of bladder tumor (TURBT) based on clinicopathological factors alone. However, prediction of recurrence using biomolecular characteristics of bladder tumors has not been applied to clinical practice. The objective of this study was to establish a new gene expression scoring system for identifying patients at high risk of recurrence.
METHODS: NMIBC and normal bladder samples were subjected to microarray analysis to obtain gene expression profiles. We identified 6 genes that were specifically upregulated in bladder cancer and also in recurrent cases. All patients were randomly grouped into a discovery cohort (n = 59) and a validation cohort (n = 30). Gene expression score (GES) was defined as the mean Z-score of the 6 genes specific for recurrent bladder cancer.
RESULTS: The intravesical recurrence rate of the high GES group (n = 38) was higher than the low GES group (n = 21). GES was significantly associated with recurrence-free survival in the validation cohort as well. In prognostic analysis, the European Organization for Research and Treatment of Cancer (EORTC) risk classification was not related to recurrence after TURBT in either univariate or multivariate analysis. On the other hand, the GES we developed was an independent factor for recurrence in NMIBC.
CONCLUSIONS: A novel gene expression scoring system was shown to predict recurrence in NMIBC patients after TURBT and might be helpful in clinical decision-making for NMIBC patients.
The present invention relates to compound injection preparation which contains effective parts of traditional Chinese medicine for treating angiocarpy and cerebral vessel diseases, and a preparation method. One part of borneol which is traditional Chinese medicine by weight and 2 to 20 parts of gingko leaf extract by weight are combined according to a compounding ratio, which prepares the compound preparation, and the compound injection preparation is also prepared. The compound injection preparation of the present invention enhances the pharmacological action and the effect time of traditional oral medicine. Compared with a mode that one of borneol and gingko leaf extract is singly used, the medicine effect is obviously enhanced, and attenuation of virulence is obtained. The compound injection preparation is used for treating cerebral infarction, cerebral ischemia, coronary heart diseases, angina pectoris, myocardial infarction, etc. The compound injection preparation has the characteristics of quick effect, obvious effect, high safety and high stability.
Lactoferrin is a highly conserved, monomeric 80 kDa single polypeptide chain contained in most mammalian exocrine secretions, such as milk, saliva and tears, bronchial, and intestinal secretions. LTF is also found in the secondary granules of neutrophils a glycoprotein present in milk, has been demonstrated to possess a multitude of biological functions. Lactoferrin in Inflammation and Sepsis The antimicrobial activity of LTF is well documented and consists of two mechanisms: one is iron dependent and deals with high affinity of LTF to iron (bacteriostatic), and the other one is due to LTF affinity to lipopolysaccharide (LPS) to function as a direct bactericidal agent for Gram-negative organisms. Small changes, such as single nucleotide polymorphisms, can affect outcomes against pathogenic agents . LTF interacts with cell surface receptors involved in "danger signal" recognition \[e.g., toll-like receptor (TLR)4, CD14, and CD22\]. At the molecular level, LTF seems to reduce LPS-induced monocyte activation and subsequent production of pro-inflammatory mediators. Lactoferrin in Anemia in Liver Disease The hepatic expression of the hepcidin gene is regulated by signals which reflect body iron status and erythropoietic activity. The regulation of hepcidin by iron status includes a signal from the circulating transferrin via hepatocellular transferrin receptor (TfR2). Like transferrin, lactoferrin will deliver iron to hepatocytes but unlike transferrin, lactoferrin cannot deliver iron to erythroid cells. Lactoferrin does not interact with TfR1 or TfR2.
INTRODUCTION: Sepsis is characterized by a dysregulated innate immune response. It is a leading cause of morbidity and mortality in newborns, in particular for newborns that are born premature. Although previous literature indicate that the pro-inflammatory response may be impaired in preterm newborns, serum levels of monocyte-derived cytokines, such as TNF-α and IL-6, vary highly between newborns and can reach adult-like concentrations during sepsis. These contradictory observations and the severe consequences of neonatal sepsis in preterm newborns highlight the need for a better understanding of the pro-inflammatory cytokine response of preterm newborns to improve sepsis-related outcomes.
METHODS AND RESULTS: Using an in vitro model with multiple read outs at the transcriptional and protein level, we consistently showed that the monocyte-derived cytokine response induced by sepsis-related bacteria is comparable between preterm newborns, term newborns and adults. We substantiated these findings by employing recombinant Toll-like receptor (TLR) ligands and showed that the activation of specific immune pathways, including the expression of TLRs, is also similar between preterm newborns, term newborns and adults. Importantly, we showed that at birth the production of TNF-α and IL-6 is highly variable between individuals and independent of gestational age.
DISCUSSION: These findings indicate that preterm newborns are equally capable of mounting a pro-inflammatory response against a broad range of bacterial pathogens that is comparable to term newborns and adults. Our results provide a better understanding of the pro-inflammatory response by preterm newborns and could guide the development of interventions that specifically modulate the pro-inflammatory response during sepsis in preterm newborns.
In Belgium, HIV pre-exposure prophylaxis (PrEP) services are mainly provided through specialised HIV clinics. To optimise PrEP uptake and retention in care, we require insights into users' perspectives on PrEP care. We aimed to elicit experiences with, and preferences for, PrEP service delivery among PrEP users in Belgium, including willingness to involve their family physician (FP) in PrEP care. We adopted a sequential mixed-methods design. We used a web-based longitudinal study among 326 PrEP users that consisted of two questionnaires at six-month intervals, and complemented this with 21 semi-structured interviews (September 2020-January 2022). We conducted descriptive analyses and logistic regression to examine factors associated with willingness to involve their FP in PrEP care. Interviews were analysed using thematic analysis. Survey respondents reported high satisfaction with care received in HIV clinics [median score 9 (IQR 8-10), 10='very satisfied']. Interviews revealed the importance of regular HIV/STI screening, and the expertise and stigma-free environment of HIV clinics. Yet, they also contextualised service delivery barriers reported in the questionnaire, including the burden of cost and challenges integrating PrEP visits into their private and professional lives. Although 63.8% (n = 208/326) of baseline respondents preferred attending an HIV clinic for PrEP follow-up, 51.9% (n = 108/208) of participants in the follow-up questionnaire reported to be willing to have their FP involved in PrEP care. Participants reporting trust in FPs' PrEP and sexual health expertise, or who didn't feel judged by their FP, were more likely to be willing to involve them in PrEP care. Therefore, we recommend a differentiated PrEP service delivery approach, including involving FPs, to make PrEP care more client-centred.
Single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
Atrial fibrillation (AF) is a common arrhythmia, and out-of-hospital, wearable, long-term electrocardiogram (ECG) monitoring can help with the early detection of AF. The presence of a motion artifact (MA) in ECG can significantly affect the characteristics of the ECG signal and hinder early detection of AF. Studies have shown that (a) using reference signals with a strong correlation with MAs in adaptive filtering (ADF) can eliminate MAs from the ECG, and (b) artificial intelligence (AI) algorithms can recognize AF when there is no presence of MAs. However, no literature has been reported on whether ADF can improve the accuracy of AI for recognizing AF in the presence of MAs. Therefore, this paper investigates the accuracy of AI recognition for AF when ECGs are artificially introduced with MAs and processed by ADF. In this study, 13 types of MA signals with different signal-to-noise ratios ranging from +8 dB to -16 dB were artificially added to the AF ECG dataset. Firstly, the accuracy of AF recognition using AI was obtained for a signal with MAs. Secondly, after removing the MAs by ADF, the signal was further identified using AI to obtain the accuracy of the AF recognition. We found that after undergoing ADF, the accuracy of AI recognition for AF improved under all MA intensities, with a maximum improvement of 60%.
A WCD system is configured to detect when a therapy administered to a patient by the WCD system is unsuccessful, and in response determine whether to send notifications to remote non-witness responders. The WCD system may be configured to decide to send such notifications after the WCD system determines it has administered a predetermined number of unsuccessful shocks to the patient. The predetermined number of unsuccessful shocks may be the maximum number of unsuccessful shocks the WCD system will administer to a patient, or every Xth shock (e.g., 3rd shock). The WCD system can be configured to periodically resend the notification. The notifications may be in the form of SMS, voice messages, emails, app notifications, etc. sent to cell phones, smartphones, computers, laptops, tablets, etc. of the responders either directly, via a server, or via a CAD-coupled server.
One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
The present invention relates to a recombinant hemagglutinin protein antigen composition derived from influenza viruses. More specifically, the present invention relates to an antigen composition for preventing or treating orthomyxoviruses, wherein the antigen composition comprises influenza virus recombinant hemagglutinin monomeric protein dual modified protein as an active ingredient. The antigen composition according to the present invention has a very excellent prevention effect of inhibiting proliferation and reproduction of orthomyxoviruses, and thus can be used as a preventing or treating agent which is effective for influenza viruses along with avian influenza. Since recombinant hemagglutinin monomeric protein is used, reutilization and safety are acknowledged. Therefore, when a material including an antigen composition is provided, animal influenza diseases including birds and human bodies can be reduced. Thus, the present invention can be widely utilized in various industrial fields such as medical fields and life science filed, and is expected to be a very meaningful development socially and economically.
Provided are a siRNA inhibiting SCN9A gene expression, a pharmaceutical composition and a use thereof. The siRNA comprises a sense strand and an antisense strand. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The sense strand comprises a nucleotide sequence of the following sequence or has no more than 3 base mutations from the following sequence. The antisense strand comprises a nucleotide sequence of the following sequence or has no more than 5 base mutations from the following sequence. The sequence of the siRNA is as shown in SEQ ID NO:1 to SEQ ID NO:32. The provided siRNA, a conjugate and a pharmaceutical composition thereof can effectively inhibit expression of the SCN9A gene.
<P>PROBLEM TO BE SOLVED: To provide an eating and drinking type hair growth-promoting agent that can promote the hair growth.  <P>SOLUTION: This gray hair-suppressing composition includes soybean extract and seaweed extract as essential components. In addition to these soybean extract and seaweed extract, an extract of zooplankton is also added to prepare another gray hair-suppressing composition. In another case, an extract of sesame is added to another composition including soybean extract, seaweed extract and an extract of zooplankton to obtain another gray hair suppressing composition. The solution including these composition is fermented with Bacillus natto and the resultant fermented solution is used as a component for the composition. As a seaweed, is used a mixture of Monostroma nitidum, Enteromorphasp and Ulva pertusa in the compositions. Krill britt is used as a zooplankton in these composition. These compositions are used to provide the gray hair-suppressing cosmetics. These compositions are used to produce drinking or eating type gray hair-suppressing cosmetics.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Pocket-Assisted Visual Inspection with Acetic Acid (PA-VIA): The cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied using a spray bottle or fox swab. After approximately 1-minute, using the Pocket Colposcope any changes to the cervix will be noted. Using the Calla Health image acquisition software, both white and green images of the cervix will be captured at low-resolution. Acetic acid may be reapplied between white and green imaging at the provider's discretion if acetowhitening diminishes. Images will be acquired. A biopsy will be obtained using the pocket. Random biopsies will be obtained from 2 quadrants in the absence of a visible lesion.
Factorial quasi-randomization is utilized to compare two groups of interventions (i.e., GHPP and CS) as well as to compare these individual interventions with a combination of the interventions. It is also possible that distinct treatments have interaction effects, and we plan to test for this. Policymakers are interested in using different strategies to enhance neonatal health. For example, the bank of SMS developed by our team is a combination of several components: reminders for regular checkups, information on GHPP, and information on CS. From a policy perspective, the evaluation of the full bank of SMS may be sufficient for the government to decide whether or not to scale up the full bank of SMS. However, to understand maternal behavior and, for policy purposes, to understand which components in the bank of SMS should be scaled up, it is important to disentangle which component contributes most to final neonatal health. Taken together, are all the components of the bank of SMS effective in changing maternal behavior and enhancing neonatal health? Which mechanisms are at play, good household prenatal care, care seeking in pregnancy, or both?
Antimicrobial treatment of acute otitis media has been proven efficacious in children. It has been suggested that antimicrobial treatment makes a lot of harm to intestinal microbiome and may thus have effects on the child's health and wellbeing. However, data on these changes and their magnitude is scanty. This is a randomized, controlled trial studying the effects of various antimicrobial treatments on the intestinal microbiome of small children. The participating children with acute otitis media are treated wither with amoxicillin, amoxicillin-clavulanate or without antibiotics. The children with allergy to amoxicillin receive a course of macrolide and they will be monitored as a separate group. The main outcomes of this trial are the changes in the intestinal microbiome after the treatment.
BACKGROUND: The percentage of smokers who develop COPD (Chronic Obstructive Pulmonary Disease) peaks at 40-50% in most recent publications.
SUMMARY: Tobacco smoke remains the main cause of COPD, though smoking-related limitation of the flow is rather subjective. For patients who keep on smoking, general practitioners (GPs) and pulmonologists should be able to offer smoking cessation programs as an important part of COPD treatment. This narrative article aims to provide the scientific basis to help healthcare professionals develop this therapy; with this aim in mind, the authors have analyzed the most recent literature.
KEY MESSAGES: Only 3% of smokers who try to quit without availing themselves of any support succeed. Effective smoking cessation methods are counselling and pharmacotherapy, which, combined together, are credited with a 24% success rate. Although there are no therapeutic novelties with strong scientific evidence for smoking cessation, it is however advisable to keep the literature updated to new devices and new digital therapies.
PCT No. PCT/NL95/00279 Sec. 371 Date Feb. 25, 1997 Sec. 102(e) Date Feb. 25, 1997 PCT Filed Aug. 22, 1995 PCT Pub. No. WO96/06112 PCT Pub. Date Feb. 29, 1996Antigenic substance or precursor thereof comprising a peptide part derived from an amino acid sequence located between two mucin-like regions of a protein G of a respiratory syncytial virus (RSV). Said andgenic substance or precursor thereof allows to discriminate between, or identify, different types or subtypes of respiratory syncytial viruses, or antibodies against them. In preferred embodiments, the peptide part is derived from protein G of bovine respiratory syncytial virus, human respiratory syncytial virus A, human respiratory syncytial virus B, or ovine respiratory syncytial virus. Use of the antigenic substance or precursor thereof (in vaccines) for prophylaxis of RSV infections, in assays and testkits for detecting or identifying (antibodies against) RSV types or subtypes, and in methods for obtaining antibodies against RSV types or subtypes. Use of such antibodies in assays and testkits for detecting or identifying RSV types or subtypes.
The invention discloses herbal decoction for treating hemorrhoids, belonging to the decoction of Chinese traditional medicine. The raw materials in the prescription of the invention include 5-15g of processed radix phytolaccae (pokeberry root), 3-6g of processed radix sophorae flavescentis (lighiyellow sophora root), 10-12g of panax notoginseng powder, 3-6g of tree peony bark, 6-9g of pearl powder and 6-9g of gypsum powder. The herbs are mixed and boiled in water, and the herbal liquid is maintained; one dose is taken for one day and is separated into two parts for twice oral taking in a day. The herbal liquid can be used as lotion. The decoction can be prepared as fumigant, granules or capsules. The invention is applied for treating hemorrhoids in various levels and mild anal fissure or anal sinusitis.